1. Introduction
===============

Hepatitis B virus (HBV) infection is a serious worldwide health burden.^\[[@R1]\]^ China is a highly endemic area with hepatitis B surface antigen (HBsAg) positive rate about 10%.^\[[@R2]\]^ HBV mainly spreads through blood, mother--infant, and sexual transmission.^\[[@R2],[@R3]\]^ The vertical transmission of mother and infant is the main route of transmission of HBV in China. At present, the most effective mother--infant blockade is to perform active--passive double immunization with HBV vaccine combined with hepatitis B immunoglobulin (HBIG) within 24 hours after birth.^\[[@R4]\]^ However, there are still 5% to 10% of infants who have immune failure.^\[[@R4],[@R5]\]^ The mother-to-infant transmission of HBV mainly includes intrauterine transmission (prenatal delivery), transmission during childbirth, and postpartum transmission. The cause of HBV vertical transmission block failure has not been fully understood. It is generally believed that the main factors include HBeAg-positive, HBV-DNA high viral load, intrauterine infection, and viral mutation.^\[[@R5]--[@R7]\]^ Among them, intrauterine infection is the main reason for the failure of active and passive dual immunization.

Nucleoside analogs inhibit HBV-DNA replication and are currently approved to anti-HBV treatment.^\[[@R8]--[@R10]\]^ Among them, tenofovir (TDF) and telbivudine (LdT), which can rapidly reduce serum HBV-DNA levels, were used to block vertical transmission of HBV. In previous study, LdT did not determine mutations, carcinogenesis, and associated embryonic or fetal toxicity in animal experiment.^\[[@R11],[@R12]\]^ Therefore, LdT is approved by FDA for blocking vertical transmission of HBV. However, the drug resistance barrier of LdT is low.^\[[@R13]\]^ TDF is another effective anti-HBV drug due to its potency and high resistance barrier.^\[[@R14],[@R15]\]^ In HIV monoinfected and HIV/HBV c-infected mothers, it was reported that TDF had a favorable efficacy and safe profile to block vertical transmission.^\[[@R16],[@R17]\]^ However, to our knowledge, there are limited data available in the literature to compare the effectiveness of TDF and LdT therapy during pregnancy in highly viremic mothers with chronic hepatitis B and its impact on the perinatal transmission of HBV.

To identify effective approaches for preventing mother-to-infant transmission of HBV, the present study evaluated the efficacy and safety of LdT and TDF for treating HBV-positive pregnant women.

2. Methods
==========

2.1. Patients
-------------

The Institutional Review Board had approved the study. Pregnant women (n = 145) from January 2013 to June 2017 who met the following inclusion criteria were enrolled: 20 to 35 years old; 20 to 28 weeks gestation; HBsAg and HBeAg-positive, and HBV DNA ≥1.0 × 10^7^ copies/mL; elevated alanine aminotransferase (ALT) ≥2 upper limit of normal.

ALT levels were examined using the Olympus AU5400 biochemical analyzer (Tokyo, Jpan). Levels of HBV serological markers were determined using a commercially available radioimmunoassay (ARCHITECT i2000SR, Abbott Laboratories, Lake Bluff, IL) and serum HBV DNA viral load was detected using Daan real-time PCR test (Daan Gene Co, Ltd of Sun Yat-sen University, Guangdong, China, with linear range of 10^2^--10^8^ IU/mL).

Criteria for exclusion were as followed: patients have received interferon or other nucleos(t)ide analogues treatment previously, coinfected with hepatitis C virus, hepatitis D virus, hepatitis E virus, and HIV and received treatment of immunosuppressive or cytotoxic drugs, or corticosteroids during pregnancy.

2.2. Grouping and management
----------------------------

The patients were allocated to 3 groups according to their antiviral agents. Patients who received LdT were assigned to Group A. Patients who received TDF were assigned to Group B. patients in Group C received no antiviral therapy. Maternal blood samples were collected before treatment, before delivery, and at 12 weeks postpartum to detect HBV DNA and ALT levels.

All infants born to the enrolled women were vaccinated with 200 IU of HBIG within 6 hours. Then they were vaccinated with 20 μg of hepatitis B vaccine within 12 hours after birth, and at postpartum 4 and 24 weeks. The following data were collected at birth: height, weight, head circumference, 1-minute Apgar score, and birth defects (the presence of any deformities). In addition, adverse pregnancy events (e.g., eclampsia, premature rupture of membranes, and premature delivery), postpartum hemorrhage, and cesarean section were recorded. Serum HBsAg in infants were tested at 6 and 12 month postpartum.

2.3. Statistical analyses
-------------------------

The data were analyzed using software SPSS 17.0 (Chicago). The chi-squared test was applied to compare categorical variables among groups. Continuous variables are presented as mean ± standard deviation. Differences among groups were compared with ANOVA test. *P* \< .05 was considered statistically significant.

3. Results
==========

3.1. Pregnancy characteristics of patients enrolled
---------------------------------------------------

In this study, 145 pregnant women were enrolled and 58 of them treated with LDT while 51 treated with TDF during pregnancy. All infants enrolled have neonatal standard immunoprevention. Clinical characteristics of patients in Groups A, B, and C were similar with regard to age, gravidity, delivery, and gestational age at delivery, as shown in Table [1](#T1){ref-type="table"}.

###### 

Pregnancy characteristics and safety rates of the 3 groups.

![](medi-98-e15092-g001)

3.2. Serum HBV DNA levels before and after treatment
----------------------------------------------------

The dynamic changes of serum HBV DNA level were shown in Figure [1](#F1){ref-type="fig"}. Serum HBV DNA levels of the 3 groups were similar (Group A vs. Group B vs. Group C, 7.88 ± 0.65 vs. 7.91 ± 0.75 vs. 7.69 ± 0.53, *P* = .25). The HBV DNA viral load in Groups A and B were significantly decreased after treatment in Group A and B. The serum HBV DNA levels in both Groups A and B were lower than that of Group C (*P* \< .01, both). There were no significant differences in HBV DNA levels between Groups A and B before delivery or at 12 weeks postpartum.

![The dynamic changes of serum HBV DNA level in groups. Serum HBV DNA levels of the 3 groups were similar at baseline (Group A vs. Group B vs. Group C, 7.88 ± 0.65 vs. 7.91 ± 0.75 vs. 7.69 ± 0.53 log~10~ copies/mL, *P* = .25). The HBV DNA viral load in Groups A and B were significantly decreased after treatment (2.52 ± 1.33 and 1.64 ± 1.31 log~10~ copies/mL in Group A and B). The serum HBV DNA levels in both Groups A and B were lower than that of Group C (*P* \< .01, both), while no significant differences observed in HBV DNA levels between Groups A and B before delivery and at 12 weeks postpartum. HBV = hepatitis B virus.](medi-98-e15092-g002){#F1}

3.3. ALT levels before and after treatment
------------------------------------------

The dynamic changes of serum ALT level were shown in Figure [2](#F2){ref-type="fig"}. There were no significant differences in ALT level among Groups A, B, and C (*P* = .171). The differences between A and C, and between B and C were statistically significant before delivery (*P* \< .01), as well as at week 12 postpartum (*P* \< .01). There were no significant differences in ALT level between Groups A and B before delivery or at postpartum 12 weeks.

![The dynamic changes of serum ALT level were shown. There were no significant differences in ALT level among Groups A, B, and C (127.3 ± 72.2, 143.3 ± 104.6, and 132.3 ± 78.3 in Group A, B, and C, *P* = .171). The differences between A and C, and between B and C were statistically significant before delivery (62.5 ± 53.7, 54.8 ± 41.2, and 154.6 ± 67.8 U/L in Group A, B, and C, *P* \< .01), as well as at week 12 postpartum (29.9 ± 19.8, 29.8 ± 23.8, and 146.6 ± 89.8 U/L, *P* \< .01). There were no significant differences in ALT level between Groups A and B before delivery or at postpartum 12 weeks. ALT = alanine aminotransferase.](medi-98-e15092-g003){#F2}

3.4. Safety of LdT and TDF during pregnancy
-------------------------------------------

The clinical characteristics of infants were shown in Table [2](#T2){ref-type="table"}. There were no significant differences in body weight, height, head circumference, or Apgar score among the infants among the 3 groups. Furthermore, there were no significant differences in the incidence of adverse pregnancy events (including eclampsia, premature rupture of membranes, premature birth, postpartum hemorrhage, or cesarean section) (Table [1](#T1){ref-type="table"}). In addition, there were no virologic resistance found assessed by evaluating genotypic changes using HBV polymerase/reverse transcriptase assay.
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General conditions of infants in the 3 groups.
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3.5. Infant HBV infection rate at week 28 postpartum
----------------------------------------------------

The HBsAg positivity rates of infants in Groups A, B, C at postpartum 6 months and 12 months were 0%, 0%, and 11.1%, respectively (*P* \< .001, Table [3](#T3){ref-type="table"}). The differences in HBV infection rate between Groups A and C (*P* \< .01) and between Groups B and C (*P* \< .01) were statistically significant. However, there is no difference observed in HBV infection rate in Group A and Group B.
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HBV infection of infants in the 3 groups.
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4. Discussion
=============

Our findings showed no vertical transmission in patients receiving LdT or TDF treatment while a vertical transmission rate of 11.1% occurred in patients receiving no anti-HBV treatment, which confirmed the effectiveness of anti-HBV treatment during pregnancy to block vertical transmission. In this retrospective study, the 109 patients in Group A and B receiving anti-HBV drugs during pregnancy did not have complications observed.

Recently, evidence-based medicine has been used to confirm the safety of anti-HBV drugs during pregnancy.^\[[@R18],[@R19]\]^ The experience of human beings using anti-HBV treatment during pregnancy is mainly from lamivudine.^\[[@R4],[@R20]\]^ There are increasing safety data of LdT to prevent vertical transmission in clinical practices.^\[[@R11],[@R21]--[@R23]\]^ Many studies reported that TDFs are effective to prevent vertical transmission in HIV-infected mother.^\[[@R16],[@R17]\]^ Among 5 FDA approved oral anti-HBV agents, TDFs are the most effective agents due to their resistance profile and potency.^\[[@R24],[@R25]\]^ However, limited data were presented to compare the effectiveness of LdT and TDF during pregnancy. TDF and LdT are classified as category B for use in pregnancy. According the results of our study, both LdT and TDF are effective and safe used in pregnant mother to block HBV vertical transmission.

This study has some limitations. This is a retrospective study, so data and conclusions may be biased. Prospective controlled studies of pregnancy are still needed. In view of the serious medical and social problems of pregnancy and anti-HBV treatment, how to maximize the risk avoidance and maximize the benefits, we need to accumulate more evidence-based data.
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